# Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

> **NCT03050086** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioPharmX, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Moderate to Severe Papulopustular Rosacea

## Interventions

- **DRUG:** BPX-04 1% minocycline topical gel
- **DRUG:** BPX-04 2% minocycline topical gel
- **DRUG:** BPX-04 vehicle topical gel

## Key facts

- **NCT ID:** NCT03050086
- **Lead sponsor:** BioPharmX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-29
- **Primary completion:** 2018-06-19
- **Final completion:** 2018-06-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050086, "Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03050086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*